| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,624.9 | 1,576.7 |
| Profit before tax | 81.0 | -2.2 |
| Net income | 44.5 | -23.5 |
| EPS (diluted, $ a share) | $0.31 | $-0.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +3.1% |
|---|
10-Q filed with the SEC, NYSE: ARDT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ardent Health, Inc.: key numbers
- Share price
- $17.75Close, Nov 17
- Market cap
- $2.5B
- Shares outstanding
- 140.94MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-General Medical & Surgical Hospitals, NECSIC 8062
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ardent Health, Inc.
All →Ardent Health Signs $47M M&A Deal with Boone Health
Ardent Health (NYSE: ARDT) has entered into a definitive agreement to acquire Boone Health, a Missouri-based not-for-profit health system, for $47 million in cash. The deal includes a 392-bed hospital and 19 sites of care, with Ardent committing an additional $200 million in capital investments over the next 10 years. The transaction is expected to close in Q1 2027 and be 6-8% accretive to Ardent's Adjusted EBITDA by the third year.
- Value
- $47M
- Counterparty
- Boone Health
Ardent Health Financial Results
Ardent Health reported third quarter 2026 total revenue of $1.62 billion, a 3.1% increase year-over-year, and net income of $45 million. The company raised its full-year 2026 Adjusted EBITDA guidance midpoint by 1.5% based on year-to-date performance and operational momentum from its IMPACT initiatives.
“We delivered strong third quarter results, highlighted by adjusted EBITDA of $138 million, a 4% reduction in SWB expense, and 2.9% adjusted admissions growth. Our performance reflects disciplined execution, with volumes improving sequentially and continued progress on our operating priorities. IMPACT initiatives continued to gain traction and remain on track to achieve at least $70 million of savings this year, contributing to greater efficiency and stronger financial performance.”
Dave Caspers, President and Chief Executive Officer of Ardent Health
“We enter the fourth quarter with confidence in the trajectory of our business and ability to execute on the opportunities ahead. Based on our year-to-date performance and continued operational momentum, we are raising our 2026 Adjusted EBITDA guidance midpoint 1.5%.”
Dave Caspers, President and Chief Executive Officer of Ardent Health
Ardent Health Leadership Change
Ardent Health has recharacterized the June 2026 departure of former President and CEO Martin J. Bonick as a termination for 'Cause' following a board review of undisclosed third-party compensation. As a result, the company is discontinuing approximately $4.5 million in remaining cash severance payments and cancelling all of Mr. Bonick's outstanding unvested performance-based restricted stock units.